Cognitive Impairment and Neuropsychiatric Manifestations of Neurobrucellosis

NCT04301752 — Completed, 82 participants, Mansoura University Hospital

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT04301752
StatusCompleted
Study typeObservational
Enrollment82 (Actual)
SponsorMansoura University Hospital (Other)
ConditionsBrucellosis
InterventionsMoCA (Diagnostic test)
Datesstart 2019-02-01, primary completion 2020-01-01, completion 2020-03-01, first posted 2020-03-10, last updated 2020-03-18
Locations1 site in Egypt

Related Papers Related Patents Related Grants Related Experts
All trials for Brucellosis All trials of MoCA

-Summary

Brucellosis is a common zoonotic infection in many parts of the world including the Mediterranean and Middle Eastern countries.

Neurobrucellosis may develop at any stage of disease and may have widely variable manifestations, including encephalitis, meningoencephalitis, radiculitis, myelitis, peripheral and cranial neuropathies, subarachnoid hemorrhage, and psychiatric manifestations.

Expand all sections  ·  Collapse all

+Detailed description

Brucellosis is a common zoonotic infection in many parts of the world including the Mediterranean and Middle Eastern countries.

Neurobrucellosis may develop at any stage of disease and may have widely variable manifestations, including encephalitis, meningoencephalitis, radiculitis, myelitis, peripheral and cranial neuropathies, subarachnoid hemorrhage, and psychiatric manifestations.

The aimed is to shed light to the obscure areas of diagnosis in neurobrucellosis and have detailed general and neurologic features

+Arms and interventions

ArmTypeInterventionsDescription
NeurobrucellosisDiagnostic Test: MoCABrucellosis associated with neuropsychiatric manifestations
Non-neurobrucellosisDiagnostic Test: MoCABrucellosis not associated with neuropsychiatric manifestations
  • MoCA (Diagnostic test): Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were <26. Maximum score is 30.

+Outcome measures

Primary outcomes

  • MoCA s [24 hours]: Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were <26 .

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Patients >18 years of age with laboratory-confirmed brucellosis

Exclusion Criteria:

* Previous neuropsychiatric disease

+Locations (1)

FacilityCityCountryStatus
Mansoura University HospitalAl MansurahEgypt

+Publications

  • Results publication: Young EJ. Brucella species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone, 2010:2921-5.
  • Results publication: Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med. 2005 Jun 2;352(22):2325-36. doi: 10.1056/NEJMra050570. No abstract available. PMID 15930423
  • Results publication: Finn TB. Brucellosis. In: Cohen J, Powderly WG, eds. Infectious diseases. 2nd ed. New York: Elsevier, 2004:1665-9.
  • Results publication: Eren S, Bayam G, Ergonul O, Celikbas A, Pazvantoglu O, Baykam N, Dokuzoguz B, Dilbaz N. Cognitive and emotional changes in neurobrucellosis. J Infect. 2006 Sep;53(3):184-9. doi: 10.1016/j.jinf.2005.10.029. Epub 2006 May 2. PMID 16647757

+Investigators